Literature DB >> 15102953

Different structural states of the proteolipid membrane are produced by ligand binding to the human delta-opioid receptor as shown by plasmon-waveguide resonance spectroscopy.

Isabel D Alves1, Scott M Cowell, Zdzislaw Salamon, Savitha Devanathan, Gordon Tollin, Victor J Hruby.   

Abstract

Understanding structure-function relationships and mechanisms of signal transduction in G-protein-coupled receptors (GPCRs) is becoming increasingly important, both as a fundamental problem in membrane biology and as a consequence of their central role as pharmacological targets. Their integral membrane nature and rather low natural abundance present many challenging problems. Using a recently developed technique, plasmon-waveguide resonance (PWR) spectroscopy, we investigated the structural changes accompanying the binding of ligands to the human delta-opioid receptor (hDOR) immobilized in a solid-supported lipid bilayer. This highly sensitive technique can directly monitor changes in mass density, conformation, and orientation occurring in such thin proteolipid films. Without requiring labeling protocols, PWR allows the direct determination of binding constants in a system very close to the receptor's natural environment. In the present study, conformational changes of a proteolipid membrane containing the hDOR were investigated upon binding of a variety of peptide and nonpeptide agonists, partial agonists, antagonists, and inverse agonists. Distinctly different structural states of the membrane were observed upon binding of each of these classes of ligands, reflecting different receptor conformational states, and the formation of each state was characterized by different kinetic properties. Binding constants, obtained by quantifying the extent of conformational change as a function of the amount of ligand bound, were in good agreement with published values determined by radiolabeling methods. The results provide new insights into ligand-induced GPCR functioning and illustrate a powerful new protocol for drug development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102953     DOI: 10.1124/mol.65.5.1248

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

Review 1.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  Plasmon resonance methods in GPCR signaling and other membrane events.

Authors:  I D Alves; C K Park; V J Hruby
Journal:  Curr Protein Pept Sci       Date:  2005-08       Impact factor: 3.272

3.  Photoinduced transformations in bacteriorhodopsin membrane monitored with optical microcavities.

Authors:  Juraj Topolancik; Frank Vollmer
Journal:  Biophys J       Date:  2007-01-05       Impact factor: 4.033

4.  Plasmon waveguide resonance spectroscopic evidence for differential binding of oxidized and reduced Rhodobacter capsulatus cytochrome c2 to the cytochrome bc1 complex mediated by the conformation of the Rieske iron-sulfur protein.

Authors:  S Devanathan; Z Salamon; G Tollin; J C Fitch; T E Meyer; E A Berry; M A Cusanovich
Journal:  Biochemistry       Date:  2007-05-22       Impact factor: 3.162

Review 5.  Functional membrane diffusion of G-protein coupled receptors.

Authors:  Aurélie Baker; Aude Saulière; Fabrice Dumas; Claire Millot; Serge Mazères; André Lopez; Laurence Salomé
Journal:  Eur Biophys J       Date:  2007-09-26       Impact factor: 1.733

Review 6.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

Review 7.  Plasmon-waveguide resonance (PWR) spectroscopy for directly viewing rates of GPCR/G-protein interactions and quantifying affinities.

Authors:  Victor J Hruby; Gordon Tollin
Journal:  Curr Opin Pharmacol       Date:  2007-09-14       Impact factor: 5.547

Review 8.  New paradigms and tools in drug design for pain and addiction.

Authors:  Victor J Hruby; Frank Porreca; Henry I Yamamura; Gordon Tollin; Richard S Agnes; Yeon Sun Lee; Minying Cai; Isabel Alves; Scott Cowell; Eva Varga; Peg Davis; Zdzislaw Salamon; William Roeske; Todd Vanderah; Josephine Lai
Journal:  AAPS J       Date:  2006-07-14       Impact factor: 4.009

9.  Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082).

Authors:  Mario D Aceto; Everette L May; Louis S Harris; Edward R Bowman; Charles D Cook
Journal:  Eur J Pharmacol       Date:  2007-03-19       Impact factor: 4.432

10.  Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Authors:  Teodora Georgieva; Savitha Devanathan; Dagmar Stropova; Chad K Park; Zdzislaw Salamon; Gordon Tollin; Victor J Hruby; William R Roeske; Henry I Yamamura; Eva Varga
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.